Phase 3 RATIONALE-301 Study Evaluates Tislelizumab vs Sorafenib in HCC
Ghassan K. Abou-Alfa, MD, discusses the phase 3 RATIONALE-301 trial of frontline tislelizumab vs sorafenib in patients with hepatocellular carcinoma.
Etiology Plays Role in Outcomes of Frontline HCC Trials
Ghassan K. Abou-Alfa, MD, discusses the significance of disease etiology when exploring the results of recent trials of patients with unresectable hepatocellular carcinoma.
Phase 3 Study of Camrelizumab/Rivoceranib Improves Survival vs Sorafenib in HCC
Ghassan K. Abou-Alfa, MD, discusses the data from a phase 3 trial evaluating camrelizumab and rivoceranib vs sorafenib in the first-line for unresectable hepatocellular carcinoma.
LEAP-002 Trial of Lenvatinib in uHCC Misses Co-Primary End Points
Ghassan K. Abou-Alfa, MD, discusses the LEAP-002 study of pembrolizumab plus lenvatinib vs lenvatinib alone in patients with unresectable hepatocellular carcinoma.
Case 4: Later Lines of Therapy for Patients With Recurrent HCC
Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.
Case 3: Novel Frontline Combination Strategies for Unresectable HCC
Comprehensive insight on several clinical trials analyzing frontline combination therapies for patients with unresectable hepatocellular carcinoma.
Case 3: A 63-Year-Old With Unresectable HCC Eligible for IO Therapy
In the setting of unresectable hepatocellular carcinoma, experts consider the role of frontline atezolizumab + bevacizumab given data from IMbrave150.
Case 2: Treating Child-Pugh B Metastatic Hepatocellular Carcinoma
A brief review of treatment options for patients with Child-Pugh B grade metastatic hepatocellular carcinoma.
Case 2: Adverse Event Management and Dosing of Frontline TKIs
Panelists consider the adverse event profile of frontline TKI therapy in patients with metastatic HCC and review options for dosing and dose reduction.
Case 2: PFS Subgroup Data From the REFLECT Trial in Metastatic HCC
Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.
Case 2: Data Supporting Frontline TKI Therapy in Metastatic HCC
Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.
Case 2: Selecting Frontline Therapy for Metastatic HCC
Focused discussion on the frontline treatment options available for patients diagnosed with metastatic hepatocellular carcinoma.
Case 2: Role of Biopsy and Imaging in Metastatic HCC
Panelists debate the role of imaging in conjunction with or in place of biopsy in the setting of metastatic hepatocellular carcinoma.
Case 2: A 75-Year-Old With Metastatic HCC
Shifting to a second patient case of metastatic hepatocellular carcinoma, experts consider best diagnostic practices and the initiation of therapy.
Case 1: Systemic Therapy in Combination With or Following TACE/TARE
A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.
Case 1: Role of TARE in Unresectable Hepatocellular Carcinoma
Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.
Case 1: A 60-Year-Old With Unresectable Hepatocellular Carcinoma
Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.
The Promise of Tislelizumab in Unresectable HCC
Ghassan K. Abou-Alfa, MD, discusses the use of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma, as investigated in a phase 2 clinical trial.
Abou-Alfa Gives Expert Insights for Liver Cancer Awareness Month
Ghassan K. Abou-Alfa, MD, reviews the liver cancer landscape and the collaboration of Memorial Sloan Kettering Cancer Center with other institutions to further treatments in this setting.
Key Takeaways for the Treatment of Unresectable HCC
Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.
Future of Unresectable HCC Management
Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.
Phase 3 REFLECT Trial in Unresectable HCC
Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.
Frontline Treatment Options for Unresectable HCC
An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.
Case Overview: 68-Year-Old Man With Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD, MBA, presents the case of a 68-year-old man with hepatocellular carcinoma (HCC) and shares his initial impressions.
Hepatocellular Carcinoma Treatment Landscape Evolving by the Minute, Abou-Alfa Says
Ghasson K. Abou-Alfa, MD, discusses the rapid evolution observed in the treatment landscape of hepatocellular carcinoma over the last few years.
Exploring Current Treatment Options for Patients With HCC
Ghassan K. Abou-Alfa, MD, discusses the therapies being used to treat patients with hepatocellular carcinoma right now.
Treatment Landscape for Hepatocellular Carcinoma Evolves at Rapid Pace
Ghassan K. Abou-Alfa, MD, discusses the evolution of the treatment landscape in hepatocellular carcinoma.
Analyzing the Role of Second-Line Ramucirumab in HCC
Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.
Results From the CELESTIAL Trial for Patients with Advanced HCC
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.
An Overview of a Trial Exploring MEK162 in Advanced Biliary Cancer
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.